Fecal Microbiota Transplantation: Beyond Clostridium difficile.

Area of Science:

• Microbiology
• Gastroenterology
• Immunology

Background:

• Fecal microbiota transplantation (FMT) is a standard treatment for recurrent C. difficile infection.
• Emerging evidence suggests FMT's potential in other human diseases.
• Gut microbiota dysbiosis is implicated in numerous health conditions.

Purpose of the Study:

• To review the current evidence for FMT in treating human diseases beyond C. difficile infection.
• To explore the link between dysbiosis and FMT efficacy.
• To identify areas requiring further research.

Main Methods:

• Systematic review of existing literature.
• Analysis of case series and small prospective trials.
• Examination of studies on FMT for various gastrointestinal, hepatic, and neuropsychiatric conditions.

Main Results:

• FMT has demonstrated beneficial effects in conditions such as inflammatory bowel disease, functional gastrointestinal disorders, and non-alcoholic steatohepatitis.
• Positive outcomes are also noted in alcoholic hepatitis, hepatic encephalopathy, and neuropsychiatric disorders.
• FMT shows potential in combating antibiotic-resistant bacterial infections by restoring gut microbiota.

Conclusions:

• FMT holds promise for treating a spectrum of diseases associated with gut dysbiosis.
• Clinical responses to FMT often correlate with the restoration of gut microbiota balance.
• Large-scale, rigorous studies are essential to validate FMT's efficacy, define its limitations, and optimize its therapeutic application.